Cancer progression by the okadaic acid class of tumor promoters and endogenous protein inhibitors of PP2A, SET and CIP2A

[1]  M. Kim,et al.  An orally active, small-molecule TNF inhibitor that disrupts the homotrimerization interface improves inflammatory arthritis in mice , 2022, Science Signaling.

[2]  V. Dixit,et al.  Dying cells fan the flames of inflammation , 2021, Science.

[3]  Z. Zhu,et al.  CIP2A silencing alleviates doxorubicin resistance in MCF7/ADR cells through activating PP2A and autophagy , 2021, Clinical and Translational Oncology.

[4]  R. Hua,et al.  SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A–c‐Myc axis , 2021, Molecular oncology.

[5]  R. Clark,et al.  Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia , 2021, Cancers.

[6]  Mark N. Wass,et al.  Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line , 2021, Cells.

[7]  H. Matsumoto,et al.  Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer , 2021, Scientific Reports.

[8]  M. Desco,et al.  T cells with dysfunctional mitochondria induce multimorbidity and premature senescence , 2020, Science.

[9]  M. Snyder,et al.  Heterogeneity in old fibroblasts is linked to variability in reprogramming and wound healing , 2019, Nature.

[10]  J. Spiers,et al.  Regulation of the phosphoprotein phosphatase 2A system and its modulation during oxidative stress: A potential therapeutic target? , 2019, Pharmacology & therapeutics.

[11]  Tatsuro Watanabe,et al.  The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers , 2018, Journal of Cancer Research and Clinical Oncology.

[12]  Chun-Yu Liu,et al.  SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment , 2018, Journal of clinical medicine.

[13]  Kuen-Feng Chen,et al.  Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[14]  H. Fujiki,et al.  Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate , 2017, Journal of Cancer Research and Clinical Oncology.

[15]  C. Shiau,et al.  Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential , 2016, Oncogene.

[16]  F. Rojo,et al.  Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer , 2015, Marine drugs.

[17]  K. Khanna,et al.  The nuclear oncogene SET controls DNA repair by KAP1 and HP1 retention to chromatin. , 2015, Cell reports.

[18]  Colin J. Daniel,et al.  Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer , 2014, Proceedings of the National Academy of Sciences.

[19]  M. Copland,et al.  Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. , 2011, Blood.

[20]  A. Cheng,et al.  CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells , 2010, Oncogene.

[21]  J. Lieberman,et al.  Tumor Suppressor NM23-H1 Is a Granzyme A-Activated DNase during CTL-Mediated Apoptosis, and the Nucleosome Assembly Protein SET Is Its Inhibitor , 2003, Cell.

[22]  R. Honkanen,et al.  Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? , 2002, Current medicinal chemistry.

[23]  E. Chan,et al.  Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer , 2002, Oncogene.

[24]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[25]  Hong Guo,et al.  Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. , 1995, Biochemistry.

[26]  M. Tatematsu,et al.  An alternative theory of tissue specificity by tumor promotion of okadaic acid in glandular stomach of SD rats. , 1992, Carcinogenesis.

[27]  Marieke,et al.  Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene , 1992, Molecular and cellular biology.

[28]  D. Brautigan,et al.  Structurally different members of the okadaic acid class selectively inhibit protein serine/threonine but not tyrosine phosphatase activity. , 1992, Toxicon : official journal of the International Society on Toxinology.

[29]  M. Mumby,et al.  Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen , 1991, Molecular and cellular biology.

[30]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[31]  A. Takai,et al.  Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. , 1988, The Biochemical journal.

[32]  K. Wakamatsu,et al.  Diarrhetic Shellfish Toxin, Dinophysistoxin‐1, Is a Potent Tumor Promoter on Mouse Skin , 1988, Japanese journal of cancer research : Gann.

[33]  K. Wakamatsu,et al.  Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Matsunaga,et al.  Bioactive marine metabolites. Part 16. Calyculin A. A novel antitumor metabolite from the marine sponge Discodermia calyx , 1986 .

[35]  J. Clardy,et al.  Okadaic acid, a cytotoxic polyether from two marine sponges of the genus Halichondria , 1981 .

[36]  H. Fujiki.  Is the inhibition of protein phosphatase 1 and 2A activities a general mechanism of tumor promotion in human cancer development? , 1992, Molecular carcinogenesis.

[37]  T. Yasumoto,et al.  Isolation and structural elucidation of the causative toxin of the diarrhetic shellfish poisoning. , 1982 .